EP2574343B1 - Composition destinée à l'application sur la peau et utilisation de celle-ci - Google Patents

Composition destinée à l'application sur la peau et utilisation de celle-ci Download PDF

Info

Publication number
EP2574343B1
EP2574343B1 EP11007992.8A EP11007992A EP2574343B1 EP 2574343 B1 EP2574343 B1 EP 2574343B1 EP 11007992 A EP11007992 A EP 11007992A EP 2574343 B1 EP2574343 B1 EP 2574343B1
Authority
EP
European Patent Office
Prior art keywords
weight
oil
compound according
skin
avellana
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11007992.8A
Other languages
German (de)
English (en)
Other versions
EP2574343A1 (fr
Inventor
Ali Nahavandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnapharm & Cokg GmbH
Original Assignee
Alnapharm & Cokg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES11007992.8T priority Critical patent/ES2458124T3/es
Application filed by Alnapharm & Cokg GmbH filed Critical Alnapharm & Cokg GmbH
Priority to PL11007992T priority patent/PL2574343T3/pl
Priority to RS20140205A priority patent/RS53289B/en
Priority to EP11007992.8A priority patent/EP2574343B1/fr
Priority to SI201130146T priority patent/SI2574343T1/sl
Priority to DK11007992.8T priority patent/DK2574343T3/da
Priority to PT110079928T priority patent/PT2574343E/pt
Priority to MYPI2014000876A priority patent/MY184014A/en
Priority to CA2848922A priority patent/CA2848922C/fr
Priority to KR1020147010913A priority patent/KR101954057B1/ko
Priority to JP2014532261A priority patent/JP6034386B2/ja
Priority to GEAP201213454A priority patent/GEP20166495B/en
Priority to CN201280047464.7A priority patent/CN103841986B/zh
Priority to SG11201400742PA priority patent/SG11201400742PA/en
Priority to EA201400399A priority patent/EA023746B1/ru
Priority to AP2014007596A priority patent/AP2014007596A0/xx
Priority to US14/347,788 priority patent/US20140234447A1/en
Priority to BR112014007218-3A priority patent/BR112014007218B1/pt
Priority to PCT/EP2012/003802 priority patent/WO2013045031A1/fr
Priority to NZ623817A priority patent/NZ623817B2/en
Priority to AU2012314946A priority patent/AU2012314946B2/en
Priority to PE2014000428A priority patent/PE20141538A1/es
Priority to MX2014003846A priority patent/MX349493B/es
Priority to UAA201403936A priority patent/UA113065C2/uk
Publication of EP2574343A1 publication Critical patent/EP2574343A1/fr
Application granted granted Critical
Publication of EP2574343B1 publication Critical patent/EP2574343B1/fr
Priority to TNP2014000102A priority patent/TN2014000102A1/en
Priority to ZA2014/01941A priority patent/ZA201401941B/en
Priority to IL231589A priority patent/IL231589B/en
Priority to CL2014000756A priority patent/CL2014000756A1/es
Priority to GT201400058A priority patent/GT201400058A/es
Priority to CO14069571A priority patent/CO6930361A2/es
Priority to CY20141100296T priority patent/CY1115039T1/el
Priority to SM201400051T priority patent/SMT201400051B/xx
Priority to HRP20140386AT priority patent/HRP20140386T1/hr
Priority to HK14110592.5A priority patent/HK1197037A1/xx
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite

Definitions

  • the present invention relates to a composition for application to the skin and to its use in the treatment of skin diseases.
  • Psoriasis and atopic dermatitis are very common, chronic, non-contagious, inflammatory skin diseases.
  • Psoriasis is a chronic skin condition that causes lifelong discomfort. Approximately one in five psoriasis patients suffers from additional arthritic complaints (psoriatic arthritis) and other chronic inflammatory diseases. Due to the interplay of different clinical pictures and symptoms, life expectancy can be shortened. For both skin diseases cause and cause are not yet finally resolved. Different theories are discussed in the literature. Genetic factors, immunological changes and / or environmental influences should play a greater role.
  • T cells The production of the responsible for the body defense reactions T cells is uncontrolled, but the T cell production is a crucial factor in the regulation of the defense system of the skin.
  • an uncontrolled antibody defense is formed, which fights not only foreign but also body-own components. It comes to the misguided reproduction of skin cells. Affected areas of the skin may show severe irritation, redness, silvery scaly deposits and are sometimes thickened. Some patients have chapped skin and open wound sites.
  • the keratinized skin cells (keratinocytes) are rejected by the body. In a healthy body, this process is almost unnoticed and invisible.
  • the keratinocytes form a natural protective shield against external environmental influences in healthy skin.
  • the repair mechanism of healthy skin is carried out by targeted control of keratinocyte formation and activation of T cells. In psoriasis disease, however, cell growth is disturbed. The formation of skin cells is greatly accelerated and disproportionately many cells are formed. The increased keratinocyte formation is activated without external action and continues uncontrolled. It forms a shiny, silvery white scaly layer on the skin. The lower layers of the skin are heavily perfused due to uncontrolled cell growth and thus appear very red.
  • the pathological lesions are often distributed individually insular. Most commonly affected are areas of the skin that are stretched and constantly exposed to mechanical stress. The skin areas thicken and shed. Dandruff makes the skin harden and tends to dryness and wounds.
  • a cure of psoriasis is not possible.
  • the therapies depend on the degree of complaint, localization and area spread of the lesions.
  • Local therapies and systemic therapies which can take the form of preparations or physically, are used. Basically, moisturizing skin care products in the form of lotions, creams, oils and ointments are used in initial discomfort and general care.
  • external (topical), internal (systemic) therapy and light are used as forms of therapy. All these measures have in common that the dandruff and inflammation development should be suppressed. The goal is to restore the normal immune response balance.
  • composition of the invention should preferably be used to support the therapeutic treatment of psoriasis and atopic dermatitis.
  • a skin-applying composition comprising a dermatologically acceptable carrier and coconut oil and hazelnut oil and / or avellana oil, and nettle oil.
  • the weight ratio of dermatologically acceptable carrier coconut oil: hazelnut oil and / or avellana oil: nettle oil in a range of 1-50: 1-30: 1-50: 1-10.
  • the composition comprises almond oil.
  • the weight ratio of dermatologically acceptable carrier coconut oil: hazelnut oil and / or avellana oil: nettle oil: almond oil in a range of 1-50: 1-30: 1-50: 1-10: 1-20.
  • composition comprises TRF extract (tocotrienol-rich fraction).
  • the weight ratio of carrier coconut oil: hazelnut oil and / or avellana oil: nettle oil: almond oil: TRF extract in a range of 1-50: 1-30: 1-50: 1-10: 0-20: 1-20 lies.
  • composition further comprises bitter almond oil.
  • the weight ratio of carrier coconut oil: hazelnut oil and / or avellana oil: nettle oil: almond oil: TRF extract: bitter almond oil in a range of 1-50: 1-30: 1-50: 1-10: 0 20: 0-20: 1-10 lies.
  • composition comprises natural flavorings, preferably lavender flavor.
  • the weight ratio of carrier coconut oil: hazelnut oil and / or avellana oil: nettle oil: almond oil: TRF extract: bitter almond oil: natural flavoring in a range of 1-50: 1-30: 1-50: 1-10 : 0-20: 0-20: 0-10: 0.1-1.
  • the composition comprises: Dermatologically acceptable carrier 1-50% by weight, preferably 30-50% by weight, more preferably 40.00% by weight, coconut oil 1-30% by weight, preferably 10-30% by weight, more preferably 15-25% by weight, more preferably 17.50% by weight, Hazelnut oil and / or avellana oil 1-50% by weight, preferably 10-40% by weight, more preferably 15-35% by weight, more preferably 20-30% by weight, more preferably 25.00% by weight, nettle oil 1-10% by weight, preferably 1-7% by weight, more preferably 3.00% by weight, almond oil 0-20% by weight, preferably 5-15% by weight, more preferably, 10.00% by weight, TRF extract (tocotrienol-rich fraction) 0-20% by weight, preferably 1-10% by weight, more preferably 2-7% by weight, more preferably 3.00% by weight, Bitter almond oil 0-10% by weight, preferably 0.5-3% by weight, more preferably 1.00% by weight, flavor
  • composition of the present invention contains dermatologically-acceptable carriers, coconut oil, hazelnut oil and / or avellana oil, nettle oil and bitter almond oil
  • weight ratios are preferably in a range of 1-50: 1-30: 1-50: 1-10: 1-10.
  • it is in the form of an ointment, cream, lotion, tincture, an oil or a gel.
  • a second object is achieved by a use of the composition for the treatment of skin diseases, in particular psoriasis, neurodermatitis (atopic dermatitis), seborrhoeic dermatitis, urticaria, erythema and lichen planus and for the treatment of wounds / skin burns and corns.
  • skin diseases in particular psoriasis, neurodermatitis (atopic dermatitis), seborrhoeic dermatitis, urticaria, erythema and lichen planus and for the treatment of wounds / skin burns and corns.
  • the composition according to the invention with skin diseases, in particular psoriasis and atopic dermatitis, alleviates the associated symptoms.
  • the composition of the invention accelerates the healing of wounds / skin burns and corns. This is done in the view of the inventors due to physical effects.
  • the composition is based on natural oils as well as a common carrier base to make the composition to make it suitable for topical application.
  • the ingredients in combination have a positive effect on the regeneration of the natural skin functions.
  • the relief is due rather to moisturizing and nourishing effects.
  • the composition produces when applied to the skin a protective film that protects the affected skin from external environmental influences and supports the body's own regeneration of the skin functions.
  • the increased dehydration of the lesions is stopped and the water content in the skin layers can be regenerated.
  • the water content in the horny layer (stratum corneum) is a decisive factor for healthy skin.
  • the epidermis of healthy skin has natural barrier functions, which regulate the water balance and protect the skin from environmental influences as well as skin-damaging substances.
  • the natural barrier function is disturbed.
  • the composition according to the invention accelerates the regeneration of the normal barrier function of the skin.
  • the composition of the invention protects the skin from harmful environmental influences and allergy-causing substances.
  • the lipid components contained in the composition according to the invention also produce a cooling effect, which produces additional relief.
  • composition according to the invention cause the skin to regenerate, the formation of the natural barrier function of the skin is supported and the natural barrier function of healthy skin is restored.
  • the cream compositions listed in the table were used to test the efficacy of 49 patients with psoriasis, 33 patients with atopic dermatitis and 28 patients for the treatment of wounds / skin burns and corns.
  • the cream with the example compositions (see above) was applied 1 to 3 times a day.
  • compositions on the diseased skin were evaluated in 49 patients with psoriasis at intervals of 1, 5, 10, 20, 30, 45, 60, 75 and 90 days after the start of the application.
  • compositions on the diseased skin were evaluated in 33 patients with atopic dermatitis at intervals of 5, 10, 14, 22, 30, 45, 60, 75 and 90 days after the beginning of the application.
  • compositions on the diseased skin were evaluated in 28 patients with wounds / skin burns and corns at intervals of 1, 2, 5, 7, 9, 10 and 14 days after the beginning of the application.
  • compositions cause relief in psoriasis, atopic dermatitis and in the treatment of wounds / skin burns and corns.
  • the preferred composition has the highest most universal and overarching efficacy in all intended applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (12)

  1. Composition pour application sur la peau, comprenant un véhicule dermatologiquement acceptable et de l'huile de noix de coco et de l'huile de noisette et/ou de l'huile de Corylus avellana et de l'huile d'ortie.
  2. Composition selon la revendication 1, caractérisée en ce qu'elle comprend en outre l'extrait TRF (fraction riche en tocotriénols).
  3. Composition selon la revendication 1 ou 2, caractérisée en ce que le rapport en poids véhicule dermatologiquement acceptable : huile de noix de coco : huile de noisette et/ou huile de Corylus avellana : huile d'ortie est dans une plage de 1-50:1-30:1-50:1-10.
  4. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend en outre de l'huile d'amande.
  5. Composition selon la revendication 4, caractérisée en ce que le rapport en poids véhicule : huile de coco: huile de noisette et/ou huile de Corylus avellana : huile d'ortie: huile d'amande est dans une plage de 1-50:1-30:1-50:1-10:1-20.
  6. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend en outre l'huile d'amande amère.
  7. Composition selon la revendication 6, caractérisée en ce que le rapport en poids véhicule : huile de coco : huile de noisette et/ou huile de Corylus avellana : huile d'ortie : huile d'amande : huile d'amande amère est dans une plage de 1-50:1-30 :1-50 :1-10 :0-20 :1-10.
  8. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend en outre des arômes naturels, comprenant de préférence l'arôme de lavande.
  9. Composition selon l'une quelconque des revendications précédentes, comprenant: le véhicule dermatologiquement acceptable 1-50 % en poids, de préférence 30-50 % en poids, de préférence 40,00 % en poids, huile de coco 1-30 % en poids, de préférence 10-30 % en poids, plus préférentiellement encore de 15 à 25 % en poids, encore plus préférentiellement 17,50 % en poids, huile de noisette et/ou huile de Corylus avellana 1-50 % en poids, de préférence 10-40 % en poids, plus préférentiellement encore de 15 à 35 % en poids, plus préférentiellement encore de 20 à 30 % en poids, plus préférentiellement encore 25,00 % en poids, huile d'ortie 1-10 % en poids, de préférence 1-7 % en poids, plus préférentiellement 3,00 % en poids, huile d'amande 0-20 % en poids, de préférence 5-15 % en poids, encore plus préférentiellement 10,00 % en poids, extrait TRF (fraction riche en tocotriénol) 0-20 % en poids, de préférence 1-10 % en poids, plus préférablement 2-7 % en poids, encore plus préférentiellement 3,00 % en poids, huile d'amande amère 0-10 % en poids, de préférence 0,5-3 % en poids, plus préférablement 1,00 % en poids arôme 0-1 % en poids, de préférence 0,3-0,7 % en poids, plus préférablement, 0,50% en poids,
    dans laquelle tous les pourcentages en poids sont basés sur la quantité totale de la composition.
  10. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle se présente sous la forme d'une pommade, crème, lotion, de teinture, de l'huile ou d'un gel.
  11. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que le véhicule dermatologiquement acceptable est choisi parmi les groupes :
    a. des pommades hydrophobes
    b. des gels lipophiles
    c. des lipogels
    d. d'onguents récepteurs d'eau parmi les onguents d'absorption du type eau dans l'huile
    e. d'onguents d'absorption du type huile dans l'eau
    f. des crèmes lipophiles
    g. des lotions du type eau dans l'huile
    h. des crèmes quasi du type eau dans l'huile
    i. des crèmes hydrophiles
    j. des lotions hydrophiles
    k. des gels hydrophiles
  12. Utilisation de la composition selon l'une quelconque des revendications 1 à 10 pour le traitement de maladies de la peau, en particulier le psoriasis, l'eczéma, la dermatite atopique, la dermatite séborrhéique, l'urticaire, l'érythème et le lichen plan, ainsi que pour le traitement des plaies/brûlures et les cors.
EP11007992.8A 2011-09-30 2011-09-30 Composition destinée à l'application sur la peau et utilisation de celle-ci Active EP2574343B1 (fr)

Priority Applications (34)

Application Number Priority Date Filing Date Title
PL11007992T PL2574343T3 (pl) 2011-09-30 2011-09-30 Kompozycja do nanoszenia na skórę i zastosowanie tej kompozycji
RS20140205A RS53289B (en) 2011-09-30 2011-09-30 MIXTURES FOR THE SKIN APPLICATION, AND THEIR USE
EP11007992.8A EP2574343B1 (fr) 2011-09-30 2011-09-30 Composition destinée à l'application sur la peau et utilisation de celle-ci
SI201130146T SI2574343T1 (sl) 2011-09-30 2011-09-30 Sestavek za nanos na koĹľo in njegova uporaba
DK11007992.8T DK2574343T3 (da) 2011-09-30 2011-09-30 Sammensætning til påføring på huden og anvendelse af samme
PT110079928T PT2574343E (pt) 2011-09-30 2011-09-30 Formulação para aplicação cutânea e a sua utilização
ES11007992.8T ES2458124T3 (es) 2011-09-30 2011-09-30 Composición para aplicación sobre la piel y uso de la misma
MX2014003846A MX349493B (es) 2011-09-30 2012-09-10 Composicion que sera aplicada a la piel, y usos de la misma.
KR1020147010913A KR101954057B1 (ko) 2011-09-30 2012-09-10 피부에 적용될 수 있는 조성물 및 이의 용도
JP2014532261A JP6034386B2 (ja) 2011-09-30 2012-09-10 皮膚に塗布する組成物、およびその使用
GEAP201213454A GEP20166495B (en) 2011-09-30 2012-09-10 Composition for spreading on skin and usage thereof
CN201280047464.7A CN103841986B (zh) 2011-09-30 2012-09-10 应用于皮肤的组合物及其用途
SG11201400742PA SG11201400742PA (en) 2011-09-30 2012-09-10 Composition to be applied to the skin, and use thereof
EA201400399A EA023746B1 (ru) 2011-09-30 2012-09-10 Композиция для нанесения на кожу и ее применение
AP2014007596A AP2014007596A0 (en) 2011-09-30 2012-09-10 Composition to be applied to the skin, and use thereof
US14/347,788 US20140234447A1 (en) 2011-09-30 2012-09-10 Composition to be applied to the skin, and use thereof
BR112014007218-3A BR112014007218B1 (pt) 2011-09-30 2012-09-10 Composição para ser aplicada à pele
PCT/EP2012/003802 WO2013045031A1 (fr) 2011-09-30 2012-09-10 Composition à appliquer sur la peau, et son utilisation
MYPI2014000876A MY184014A (en) 2011-09-30 2012-09-10 Composition to be applied to the skin, and use thereof
AU2012314946A AU2012314946B2 (en) 2011-09-30 2012-09-10 Composition to be applied to the skin, and use thereof
PE2014000428A PE20141538A1 (es) 2011-09-30 2012-09-10 Composicion para ser aplicada a la piel, y uso de la misma
CA2848922A CA2848922C (fr) 2011-09-30 2012-09-10 Composition a appliquer sur la peau, et son utilisation
NZ623817A NZ623817B2 (en) 2011-09-30 2012-09-10 Composition to be applied to the skin, and use thereof
UAA201403936A UA113065C2 (xx) 2011-09-30 2012-10-09 Композиція для нанесення на шкіру та її застосування
TNP2014000102A TN2014000102A1 (en) 2011-09-30 2014-03-10 Composition to be applied to the skin, and use thereof
ZA2014/01941A ZA201401941B (en) 2011-09-30 2014-03-17 Compositions to be applied to the skin, and uses thereof
IL231589A IL231589B (en) 2011-09-30 2014-03-19 A preparation for application to the skin and its use
CL2014000756A CL2014000756A1 (es) 2011-09-30 2014-03-27 Composicion para ser aplicada a la piel que comprende un vehiculo dermatologicamente compatible, aceite de coco, de avellana y de ortiga y el uso de la misma en enfermedades a la piel.
GT201400058A GT201400058A (es) 2011-09-30 2014-03-28 Composición para ser aplicada a la piel, y uso de la misma
CO14069571A CO6930361A2 (es) 2011-09-30 2014-04-01 Composición para ser aplicada a la piel, y uso de la misma
CY20141100296T CY1115039T1 (el) 2011-09-30 2014-04-16 Συνθεση για επαλειψη στο δερμα και χρηση αυτης
SM201400051T SMT201400051B (it) 2011-09-30 2014-04-17 Composizione da applicare sulla pelle e suo uso
HRP20140386AT HRP20140386T1 (hr) 2011-09-30 2014-04-29 Pripravak namijenjen primjeni na koži i njegova upotreba
HK14110592.5A HK1197037A1 (en) 2011-09-30 2014-10-23 Composition to be applied to the skin, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11007992.8A EP2574343B1 (fr) 2011-09-30 2011-09-30 Composition destinée à l'application sur la peau et utilisation de celle-ci

Publications (2)

Publication Number Publication Date
EP2574343A1 EP2574343A1 (fr) 2013-04-03
EP2574343B1 true EP2574343B1 (fr) 2014-01-29

Family

ID=46851932

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11007992.8A Active EP2574343B1 (fr) 2011-09-30 2011-09-30 Composition destinée à l'application sur la peau et utilisation de celle-ci

Country Status (33)

Country Link
US (1) US20140234447A1 (fr)
EP (1) EP2574343B1 (fr)
JP (1) JP6034386B2 (fr)
KR (1) KR101954057B1 (fr)
CN (1) CN103841986B (fr)
AP (1) AP2014007596A0 (fr)
AU (1) AU2012314946B2 (fr)
BR (1) BR112014007218B1 (fr)
CA (1) CA2848922C (fr)
CL (1) CL2014000756A1 (fr)
CO (1) CO6930361A2 (fr)
CY (1) CY1115039T1 (fr)
DK (1) DK2574343T3 (fr)
EA (1) EA023746B1 (fr)
ES (1) ES2458124T3 (fr)
GE (1) GEP20166495B (fr)
GT (1) GT201400058A (fr)
HK (1) HK1197037A1 (fr)
HR (1) HRP20140386T1 (fr)
IL (1) IL231589B (fr)
MX (1) MX349493B (fr)
MY (1) MY184014A (fr)
PE (1) PE20141538A1 (fr)
PL (1) PL2574343T3 (fr)
PT (1) PT2574343E (fr)
RS (1) RS53289B (fr)
SG (1) SG11201400742PA (fr)
SI (1) SI2574343T1 (fr)
SM (1) SMT201400051B (fr)
TN (1) TN2014000102A1 (fr)
UA (1) UA113065C2 (fr)
WO (1) WO2013045031A1 (fr)
ZA (1) ZA201401941B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131053A1 (it) * 2013-06-25 2014-12-26 Maria Oliva Salviati Composizione che comprende ortica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5381612A (en) * 1976-12-24 1978-07-19 Fuarumatsuoiteitsushiyu Fuabur Ointment for treating psoriasis vulgaris * lichen and eczema
DE3232136A1 (de) * 1982-08-28 1984-03-01 Ruth Cegla GmbH, 7542 Schömberg Gemisch enthaltend meersalz und/oder salinensalz
KR900700117A (ko) * 1987-12-23 1990-08-11 원본 미기재 건선에 대한 치료제
US5376361A (en) * 1993-01-13 1994-12-27 Perricone; Nicholas V. Method and compositions for topical application to the skin for prevention and/or treatment of radiation-induced skin damage
DE19504914C1 (de) * 1995-02-15 1995-11-16 Goldwell Gmbh Haarwaschmittel
US6752999B2 (en) * 1995-09-20 2004-06-22 Nicholas V. Perricone Method of skin care and/or treatment using lipoic acid
RU2127584C1 (ru) * 1996-02-29 1999-03-20 Коновалов Валерий Николаевич Мазь противовоспалительного, обезболивающего и ранозаживляющего действия (варианты)
RO113110B1 (ro) * 1997-02-13 1998-04-30 Sc Apollo Sa Săpun extrafin
US5997889A (en) * 1998-02-20 1999-12-07 Omnipotent Skin Products, L.L.C. Hand and body creme for the treatment of skin ailments
US7250174B2 (en) * 1999-12-07 2007-07-31 Schott Ag Cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
US6673756B2 (en) * 2000-09-20 2004-01-06 Symrise Gmbh & Co. Kg Multiphase soaps
ITRM20030204A1 (it) * 2003-04-29 2004-10-30 Provincia Italiana Della Congregazi One Dei Figli Formulazione dermatologica.
US7060306B2 (en) * 2003-11-10 2006-06-13 Springstead Patricia R Skin formulation
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
FR2888497B1 (fr) * 2005-07-13 2010-12-24 Oreal Procede de maquillage et/ou de soin cosmetique
US20080113033A1 (en) * 2006-11-13 2008-05-15 Hrk, Inc. Topical treatment and manufacturing method
DE102007036499A1 (de) * 2007-08-01 2009-02-05 Henkel Ag & Co. Kgaa Naturkosmetisches Haarbehandlungsmittel
FR2956813B1 (fr) * 2010-02-26 2012-07-27 Lea Lab Shampooing et son utilisation

Also Published As

Publication number Publication date
CY1115039T1 (el) 2016-12-14
EP2574343A1 (fr) 2013-04-03
EA023746B1 (ru) 2016-07-29
BR112014007218B1 (pt) 2020-12-15
PE20141538A1 (es) 2014-11-18
TN2014000102A1 (en) 2015-07-01
CN103841986B (zh) 2019-09-03
EA201400399A1 (ru) 2014-07-30
IL231589A0 (en) 2014-05-28
NZ623817A (en) 2015-07-31
MX2014003846A (es) 2015-01-16
HRP20140386T1 (hr) 2014-08-01
BR112014007218A2 (pt) 2017-04-04
SG11201400742PA (en) 2014-04-28
SMT201400051B (it) 2014-07-07
GEP20166495B (en) 2016-06-27
MX349493B (es) 2017-08-01
JP6034386B2 (ja) 2016-11-30
PT2574343E (pt) 2014-05-02
KR20140090985A (ko) 2014-07-18
MY184014A (en) 2021-03-17
CL2014000756A1 (es) 2014-10-03
AU2012314946B2 (en) 2017-06-15
AP2014007596A0 (en) 2014-04-30
GT201400058A (es) 2015-10-15
HK1197037A1 (en) 2015-01-02
PL2574343T3 (pl) 2014-07-31
DK2574343T3 (da) 2014-04-28
WO2013045031A1 (fr) 2013-04-04
CA2848922C (fr) 2020-04-07
IL231589B (en) 2019-07-31
ES2458124T3 (es) 2014-04-30
JP2014527990A (ja) 2014-10-23
AU2012314946A1 (en) 2014-05-15
KR101954057B1 (ko) 2019-05-22
ZA201401941B (en) 2015-09-30
UA113065C2 (xx) 2016-12-12
CO6930361A2 (es) 2014-04-28
RS53289B (en) 2014-08-29
US20140234447A1 (en) 2014-08-21
CA2848922A1 (fr) 2013-04-04
SI2574343T1 (sl) 2014-06-30
CN103841986A (zh) 2014-06-04

Similar Documents

Publication Publication Date Title
DE60313597T2 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
EP0367103B1 (fr) Onguent topique
DE2046119A1 (de) Mitte) zur Behandlung der Akne
DE4431251C2 (de) Hautcreme
DE60133038T2 (de) Hypoallergenisches nichtreizendes hautpflegemittel
DE102005008299A1 (de) Universalpflegecreme
DE102007026156B4 (de) Kosmetische Zusammensetzung mit einem Limnocitrus Littoralis-Extrakt
DE202006019184U1 (de) Feuchtigkeitsspendendes Sanddorn-Hautpflegegel
EP2574343B1 (fr) Composition destinée à l'application sur la peau et utilisation de celle-ci
EP2011504B1 (fr) Produit dermatologique destiné au traitement et/ou au soin de la peau en cas de neurodermatite
DE3443242A1 (de) Glycyrrhizin und einen wirkstoff enthaltendes arzneimittel
DE69727154T2 (de) Land- und meeressschildkrötenöle, diese enthaltende zusammensetzungen, verfahren zu deren herstellung und verwendungen
EP4200285A1 (fr) Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires
DE1667890C3 (de) Dermatologische und kosmetische äußerlich anzuwendende Mittel zur Be handlung von Hautkollagenosen
CH690023A5 (de) Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
WO2003092668A1 (fr) Utilisation d'agmatine pour une application topique
DE102020133860A1 (de) VERWENDUNG VON β-GALAKTOOLIGOSACCHRIDEN FÜR DIE HERSTELLUNG EINER KOSMETISCHEN UND/ODER PHARMAKOLOGISCH WIRKSAMEN ZUSAMMENSETZUNG
DE19960633A1 (de) Kosmetisches Gesundheitspflegemittel
DE202016000224U1 (de) Wasser-in-Öl-Emulsion
DE60001278T2 (de) Behandlungsbalsam, insbesondere für oberflächliche verbrennungen und irritiere nde rötungen
WO2020234460A1 (fr) Composition à base de substances naturelles, destinée au traitement topique et au soin de la peau psoriasique et d'autres maladies de peau
WO1995011035A1 (fr) Preparation cosmetique a action antivirale pour une utilisation topique
DE102004034747B4 (de) Salbenzubereitung geeignet bei neurodermitischen Hauterkrankungen
CN116098839A (zh) 一种具有舒缓止痒功能的油溶组合物及其制备方法
DE202022001251U1 (de) Pharmazeutisches Hautpflegemittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 17/02 20060101ALI20130930BHEP

Ipc: A61K 47/06 20060101ALI20130930BHEP

Ipc: A61P 17/08 20060101ALI20130930BHEP

Ipc: A61P 17/12 20060101ALI20130930BHEP

Ipc: A61P 17/06 20060101ALI20130930BHEP

Ipc: A61K 36/889 20060101ALI20130930BHEP

Ipc: A61K 47/44 20060101ALI20130930BHEP

Ipc: A61K 36/53 20060101ALI20130930BHEP

Ipc: A61K 36/185 20060101AFI20130930BHEP

Ipc: A61K 36/736 20060101ALI20130930BHEP

Ipc: A61P 17/00 20060101ALI20130930BHEP

Ipc: A61K 9/00 20060101ALI20130930BHEP

INTG Intention to grant announced

Effective date: 20131106

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 651347

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502011002114

Country of ref document: DE

Effective date: 20140306

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20140422

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20140386

Country of ref document: HR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2458124

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140430

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20140423

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E009057

Country of ref document: EE

Effective date: 20140414

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20140400718

Country of ref document: GR

Effective date: 20140515

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20140129

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 16177

Country of ref document: SK

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20140386

Country of ref document: HR

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E020234

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502011002114

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20141030

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502011002114

Country of ref document: DE

Effective date: 20141030

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140386

Country of ref document: HR

Payment date: 20190926

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140386

Country of ref document: HR

Payment date: 20200922

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140386

Country of ref document: HR

Payment date: 20210924

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140386

Country of ref document: HR

Payment date: 20220926

Year of fee payment: 12

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230320

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E009057

Country of ref document: EE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140386

Country of ref document: HR

Payment date: 20230912

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230911

Year of fee payment: 13

Ref country code: SM

Payment date: 20230921

Year of fee payment: 13

Ref country code: RO

Payment date: 20230913

Year of fee payment: 13

Ref country code: NO

Payment date: 20230920

Year of fee payment: 13

Ref country code: NL

Payment date: 20230926

Year of fee payment: 13

Ref country code: MC

Payment date: 20230920

Year of fee payment: 13

Ref country code: LU

Payment date: 20230926

Year of fee payment: 13

Ref country code: IT

Payment date: 20230920

Year of fee payment: 13

Ref country code: IE

Payment date: 20230919

Year of fee payment: 13

Ref country code: GB

Payment date: 20230926

Year of fee payment: 13

Ref country code: FI

Payment date: 20230926

Year of fee payment: 13

Ref country code: EE

Payment date: 20230921

Year of fee payment: 13

Ref country code: BG

Payment date: 20230925

Year of fee payment: 13

Ref country code: AT

Payment date: 20230919

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230918

Year of fee payment: 13

Ref country code: SI

Payment date: 20230911

Year of fee payment: 13

Ref country code: RS

Payment date: 20230912

Year of fee payment: 13

Ref country code: PT

Payment date: 20230911

Year of fee payment: 13

Ref country code: PL

Payment date: 20230915

Year of fee payment: 13

Ref country code: IS

Payment date: 20230928

Year of fee payment: 13

Ref country code: HU

Payment date: 20230913

Year of fee payment: 13

Ref country code: HR

Payment date: 20230912

Year of fee payment: 13

Ref country code: GR

Payment date: 20230919

Year of fee payment: 13

Ref country code: FR

Payment date: 20230926

Year of fee payment: 13

Ref country code: DK

Payment date: 20230927

Year of fee payment: 13

Ref country code: DE

Payment date: 20230928

Year of fee payment: 13

Ref country code: BE

Payment date: 20230926

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20230926

Year of fee payment: 13

Ref country code: LV

Payment date: 20230922

Year of fee payment: 13

Ref country code: LT

Payment date: 20230911

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231017

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231023

Year of fee payment: 13

Ref country code: CZ

Payment date: 20231002

Year of fee payment: 13

Ref country code: CY

Payment date: 20230829

Year of fee payment: 13

Ref country code: CH

Payment date: 20231001

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20230928

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20230920

Year of fee payment: 13